Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapy for blood cancers. The success of allo-HSCT is restricted by the development of deadly graft- versus-host disease (GVHD), in 50% of allo-HSCT recipients. GVHD develops when donor T cells in the transplant (graft) become reactive against the recipient (host), triggering severe inflammatory damage. There are currently are no effective therapies for GVHD. Two key strategies for reducing GVHD are identifying biomarkers in allo-HSCT donors that may predict GVHD and developing therapeutics that target donor T cells. This thesis aimed to identify predictive donor GVHD biomarkers and develop novel therapeutic strategies to prevent GVHD that target reactive donor T cells.
Purinergic signalling is an important extracellular signalling network that is implicated in GVHD. Activation of the purinergic ATP-gated P2X7 receptor enhances GVHD in mice. Although P2X7 is present on donor and host cells in allo-HSCT, how d
Kadmon Provides Business Update and Reports Second Quarter 2021 Financial Results
pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.
Kadmon Provides Business Update and Reports Second Quarter 2021 Financial Results
theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
Kadmon Announces REZUROCK(TM) (belumosudil) Added to National Comprehensive Cancer Network(R) Clinical Practice Guidelines in Oncology for Hematopoietic Cell Transplantation
ACCESSWIRE
05 Aug 2021, 06:05 GMT+10
NEW YORK, NY / ACCESSWIRE / August 4, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced that the National Comprehensive Cancer Network
® (NCCN) added REZUROCK
TM (belumosudil) tablets to its NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
®) for Hematopoietic Cell Transplantation (HCT) in the Pre-Transplant Recipient Evaluation and Management of Graft-Versus-Host Disease (GVHD). The NCCN Guidelines in the United States now include REZUROCK with a Category 2A designation as a suggested systemic agent for steroid-refractory chronic GVHD. The rapid inclusion of REZUROCK into the NCCN guidelines shortly after full FDA approval validates the potential clinical impact of REZUROCK in this difficult-to-treat therapeutic landscape, said Harlan W. Waks
Kadmon Provides Business Update and Reports Second Quarter 2021 Financial Results
tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.